Cellular growth, proliferation and survival are regulated by a complex network of intracellular and extracellular signal transduction cascades. The growth-factor-responsive receptor tyrosine kinase (RTK)-phosphatidylinositol-3-kinase (PI3K) pathway has an important role in governing these processes 1 . The serine/threonine kinase AKT functions as a central integrator of RTK-PI3K signalling to modulate downstream effectors, most notably the TSC1/2-mTOR complexes. mTOR, a serine/threonine protein kinase and 'target of rapamycin', acts as a primary regulator of protein synthesis and cell growth 2 . Genetic studies in Drosophila and mice [3] [4] [5] [6] have shown that mTOR activity can influence cell size, an important parameter governing entry into the cell cycle 7 . mTOR also integrates diverse upstream signals that include amino acid and energy stress sensing to regulate cell proliferation, growth and survival 8, 9 . mTOR is present in two separate signalling complexes, mTOR complex 1 (mTORC1) and mTORC2, which differ in their subunit composition and their sensitivity to the bacterial macrolide rapamycin. Rapamycin inhibits mTOR activity when bound to the protein raptor, leading to reduced cell growth, cell size and proliferation 2,10,11 . A hallmark feature of human cancer is its highly rearranged genome, manifesting as numerous copy-number amplifications and deletions detectable by genome-wide array-based comparative genome hybridization (array-CGH) profiling. Reasoning that genomic alterations recurrent in different human cancer types are more likely to represent 'driver' events targeting cancer genes of broad biological and pathogenetic significance, we defined a focal amplification within a larger 5p13 regional gain present at high frequencies in several solid tumours, including melanoma, colon adenocarcinoma and nonsmall-cell lung cancer (NSCLC). Integrative genomics combined with clinicopathological and functional validation identified a Golgi-localizing protein, GOLPH3, as a new oncoprotein targeted for gene amplification at 5p13. Mechanistic studies using both yeast and human systems linked GOLPH3 to the retromer protein trafficking complex, mTOR signalling and the response to rapamycin.
GOLPH3 is a target of 5p13 amplification
Array-CGH analysis of 83 melanoma specimens showed a focal amplification within a larger 5p13 regional copy number gain, which was also present in NSCLC and colon adenocarcinomas (Fig. 1a) , prompting a broad survey by fluorescence in situ hybridization (FISH). Analysis on tumour tissue microarrays (TMA) containing 307 cores of diverse tumour types showed that 5p13 gain was present significantly in all tumour types surveyed, including 56% (27 out of 48) of NSCLC cores, 38% (18 out of 48) of ovarian carcinoma cores, 37% (16 out of 43) of prostate cancer cores, as well as 32% (12 out of 38) of melanoma cores (Fig. 1b, Supplementary Fig. 1 and Supplementary Table 1 ). Quantitative real-time PCR across the 5p13 region in informative tumour samples delimited a 0.8 megabase (Mb) minimal common region (MCR) encompassing four resident annotated genes (Fig. 1c, d ). Given that copy-number aberration (CNA) is a mechanism to drive deregulated gene expression, we next investigated the expression pattern of these resident genes in an NSCLC collection with matched expression and array-CGH profiles. As shown in Fig. 1e , only GOLPH3 and SUB1, but not MTMR12 and ZFR, showed statistically significant correlation between expression level and copy-number status, thereby pointing to GOLPH3 and SUB1 as viable candidate target(s) of this amplification.
To assess the cancer-relevance of GOLPH3, SUB1 or both, knockdown assays using pooled short interfering RNAs (siRNAs) (Fig. 1f) were performed to gauge the dependence of the human tumour (NSCLC and melanoma) cell lines on either protein for their transformed phenotype relative to the underlying copy-number status and overall expression level ( Supplementary Fig. 2a ). Knockdown of GOLPH3 resulted in considerable loss of anchorage-independent growth in CRL-5889 (NSCLC), Sbcl2 and SK-MEL-5 (melanoma) cells-three human cancer cell lines with 5p13 amplification and high expression level. However, a similar level of knockdown in 1205LU-a melanoma cell line without the 5p13 CNA and with low protein expression-resulted in minimal effect on anchorage independence (Fig. 1f) . In contrast, equally effective knockdown of SUB1 in the 5p13-amplified tumour lines had either no or relatively modest effects on anchorage independence.
To confirm that the observed knockdown activity was not due to an off-target effect of the GOLPH3 siRNA, we deconvoluted the siRNA pool and verified that two of the four independent siRNA duplexes (siRNAs 3 and 4) were effective at knocking down GOLPH3 ( Supplementary Fig. 2b ), which led to potent suppression of soft-agar growth and inhibition of proliferation in 5p13-amplified CRL-5889 cells (Fig. 2a) . Similarly effective knockdown in 1205LU without 5p13 gain and low GOLPH3 expression showed minimal effect, indicating that acute GOLPH3 depletion is not generally toxic to all cells ( Fig. 2a and Supplementary Fig. 2b) . Notably, the specificity of siRNA 3 against GOLPH3 was further documented by proliferation rescue of the NSCLC cell line, A549, by a GOLPH3 complementary DNA engineered to be insensitive to siRNA 3 (siRES) (Fig. 2b) . Together, these genetic loss-of-function studies using RNA interference (RNAi)-mediated knockdown pointed to GOLPH3 as the probable functionally active target of this amplification. Table 1 . c, Minimum common region of the 5p13 amplicon defined by array-CGH from one representative tumour (melanoma C27) with focal amplification. The y axis is the log 2 ratio compared to reference sample (pooled normal human DNA), and the x axis denotes the position on chromosome 5. d, Delimitation of chromosome 5p13 amplicon boundaries by genomic quantitative PCR using four informative cell line and tumour specimens. Samples include tumour specimens C27 (primary melanoma; red), C1 (primary melanoma; blue), CRL-5889 (NSCLC cell line; green) and Sbcl2 (melanoma cell line; yellow). Genes denoted by red font comprise 5p13 MCR; for details see Supplementary Information. Error bars indicate 6 s.d. e, Heat map depiction of Affymetrix expression data for NSCLC 5p13-amplified (Amp) and 5p13-normal specimens. Asterisks denote significant correlation after Bonferroni correction for multiple testing. f, Summary of soft agar colony counts (SA) and corresponding siRNA knockdown (% KD) of GOLPH3 and SUB1 in the indicated cell lines with amplified or normal GOLPH3 copy number. ND, not determined; NT, non-targeting. were transduced with either GOLPH3 or SUB1 to assay for the effect on anchorage-independent growth in soft agar. Error bars indicate 6 s.d. Twotailed t-test for colony number: empty vector (EV) versus GOLPH3, P 5 0.0020; empty vector versus SUB1, P 5 0.3739. e, The indicated cell lines were transduced with GOLPH3 to assay for the effect on growth of mouse xenograft tumours.
We next examined the impact of ectopic GOLPH3 expression in several model systems. GOLPH3 was capable of effecting malignant transformation of both primary non-transformed mouse and human cells. Specifically, in the classical co-transformation assay, GOLPH3 cooperated with activated HRAS(Val 12)-a constitutively active mutant in which Gly 12 is mutated to Val-to increase transformed focus formation in Ink4a/Arf (also known as Cdkn2a)-deficient primary mouse embryonic fibroblasts (MEFs) ( Fig. 2c ; 3.4-fold increase relative to HRAS(Val 12) alone). In primary human cells, GOLPH3 cooperated with oncogenic BRAF(Val600Glu) in TERTimmortalized human melanocytes (hereafter referred to as 'HMEL') 12 to confer anchorage-independent growth in soft agar, whereas SUB1 showed no transforming activity in this system (Fig. 2d) . Similar activity was also observed in the 1205LU melanoma cell line (no 5p13 amplification, low GOLPH3 expression), in which GOLPH3 overexpression ( Supplementary Fig. 2c ) enhanced anchorage-independent growth and cell proliferation in vitro ( Supplementary Fig. 2d and data not shown). Furthermore, GOLPH3 overexpression ( Supplementary Fig. 2e , f) significantly enhanced xenotransplanted tumour growth (Fig. 2e ) of human melanoma (WM239A) and NSCLC (A549) cell lines, both without 5p13 amplification. This series of reinforcing knockdown and overexpression studies demonstrates that GOLPH3 is a bona fide oncogene with potent transforming activity.
Yeast genetics links GOLPH3 to mTOR GOLPH3 (also known as GPP34, and GMx33 in rat) was initially identified as a peripheral membrane protein localized to the transGolgi network (TGN) 13, 14 . Subsequent work with the rat homologue GMx33 showed that the protein is dynamically associated with the trans-Golgi matrix, rapidly moving from the TGN to the cytosol with localization in endosomes and at the plasma membrane 15 . As a class, TGN-localizing proteins have not been directly implicated in cancer pathogenesis. Thus, we first confirmed by confocal microscopy that both exogenously expressed and endogenous human GOLPH3 indeed colocalized to the Golgi apparatus via co-immunofluorescence with the TGN marker, TGN46, and to endosome-like structures as described previously 15 ( Fig. 3a) . To gain mechanistic insights into the biological functions of GOLPH3, we screened for GOLPH3-interacting proteins using the yeast two-hybrid system (Supplementary Information and  Supplementary Table 2 ). Most notable among the GOLPH3-interacting proteins was VPS35, a highly conserved member of the cargo-recognition complex of the retromer, which regulates retrograde transport of proteins that include transmembrane receptors from endosomes to the TGN 16 . After documenting a baitdependent interaction of GOLPH3 with VPS35 in yeast (Supplementary Fig. 3a, b) , we showed a physical interaction of VPS35 with both exogenously expressed and endogenous GOLPH3 in human cells by co-immunoprecipitation ( Fig. 3b and Supplementary Fig. 3c ). Confocal co-immunofluorescence studies further confirmed the colocalization of endogenous VPS35 and GOLPH3 at endosome-like structures (Fig. 3c) .
A large-scale chemical genomic-profiling screen in Saccharomyces cerevisiae 17 has found that deletion mutants of VPS35 and VPS29 had altered sensitivity to rapamycin, an inhibitor of TOR signalling, suggesting that the retromer complex might function in the TOR signalling pathway in budding yeast. Thus, we postulated that GOLPH3 might regulate the mammalian orthologue of TOR (mTOR), thereby contributing to the pro-tumorigenic effects of GOLPH3. This hypothesis is supported by the observation that in human NSCLC tumour specimens, high 5p13 copy number was associated with increased mTOR expression and increased phosphorylation of the mTOR substrate, S6 kinase (S6K, also known as RPS6KB1) by automated 18 ( Fig. 3d and  Supplementary Tables 3 and 4) . Specifically, the mTOR expression level was associated with the cytoplasmic, but not nuclear nor total, phosphorylated-S6K(Thr 389) (pS6K) level (r 5 0.42, P 5 0.001, Pearson's correlation test). When the 5p13 copy number status was binarized into normal (with FISH-determined signal , 1.5) and gained (FISH signal $ 1.5), a significant correlation with increased mTOR (Spearman's correlation coefficient 5 0.475, P 5 0.04) and cytoplasmic pS6K (Spearman's correlation coefficient 5 0.724, P , 0.0001) was observed, indicating that 5p13 CNA is positively correlated with mTOR-pS6K activity in the adenocarcinoma subtype of NSCLC. Notably, even when the 5p13 copy number was treated as a continuous variable, significant correlation was still observed with cytoplasmic pS6K in this subtype of NSCLC (r 5 0.513, P , 0.025, Pearson's correlation test; Supplementary Table 4) . Taken together, this correlative relationship in human cancers, coupled with the yeast genetic interaction data, supports the hypothesis that GOLPH3 regulates mTOR activity in mammalian cells.
GOLPH3 activates mTOR signalling
To test the hypothesis that GOLPH3 activates mTOR signalling, we first examined the biological consequences of GOLPH3 modulation. Consistent with the role of mTOR role in cell size regulation, RNAimediated GOLPH3 depletion led to a significant cell size reduction in A549 cells, an effect that was comparable to treatment with rapamycin 19 ( Fig. 4a) . Next, we assayed the biochemical consequences of GOLPH3 modulation.
Because the mTOR substrate S6K is a kinase effector of cell size that is phosphorylated at Thr 389 by mTOR 20, 21 , we investigated phosphorylated-S6K status as a readout of the mTORC1 axis. Consistent with the human tumour data showing increased pS6K levels in 5p13-amplified NSCLC specimens, GOLPH3 overexpression resulted in increased levels of pS6K in tumour cell lines (1205LU and A549), as well as in HMEL-tet-GOLPH3 cells-a TERT-immortalized human melanocyte cell line engineered with a tetracycline (tet)-regulated GOLPH3 expression construct (Fig. 4b) . Substantiating these observations using the inducible system, GOLPH3 induction further enhanced pS6K accumulation in response to growth-factor stimulation by epidermal growth factor (EGF; Fig. 4c ). At the same time, we monitored phosphorylation of AKT (pAKT) at Ser 473, a direct substrate of mTORC2 (refs 22, 23) . Similar to the mTORC1-mediated phosphorylation of S6K, we observed a comparable increase in pAKT phosphorylation in GOLPH3-overexpressing cells (Fig. 4b) , suggesting that GOLPH3 can enhance signalling through both mTOR-associated complexes. Moreover, phosphorylation of AKT and S6K was significantly abrogated in GOLPH3-siRNA-treated NSCLC A549 and CRL-5889 cells compared to control cells in response to EGF (Fig. 4d, e) . Further biochemical analyses showed altered phosphorylation of the mTOR substrates S6K(Thr 389), p4E-BP1(Thr 37/46) (also known as EIF4EBP1(Thr 37/46)) and AKT(Ser 473), with little to no affect on other signalling proteins including PTEN, MEK1/2 (MAP2K1/2), p44 (MAPK3 and ERK1) and P42MAPK (MAPK1 and ERK2), among others ( Supplementary  Fig. 4) . Collectively, these data provided strong biochemical evidence that GOLPH3 activates mTOR signalling through phosphorylation of both mTORC1-and mTORC2-specific substrates.
GOLPH3 modulates rapamycin sensitivity
Complementing the genetic studies above, we next addressed whether GOLPH3 expression levels affect tumour cell sensitivity to pharmacological mTOR inhibition in vivo. Here we selected two human melanoma cell lines, 1205LU and WM239A, on the basis of their normal GOLPH3 copy number and low protein expression, as well as their ability to readily form subcutaneous tumours in vivo. Parental cells were engineered to stably express either empty vector or GOLPH3, for orthotopic subcutaneous transplantation into immunodeficient animals for tumour growth. Next, we compared the degree of tumour growth inhibition in GOLPH3-expressing versus empty-vector control tumours on rapamycin treatment.
Consistent with described earlier (Fig. 2e) , 1205LU-GOLPH3 cells showed a significant growth advantage compared to 1205LU-emptyvector control cells in vivo (1.9-fold increase in tumour volume at 36 days post-injection in vehicle control cohort, P 5 0.0148). After tumours reached a baseline volume of ,100 mm 3 , the animals were randomized into control and treatment cohorts for intraperitoneal injection of either vehicle or rapamycin (6.0 mg kg 21 ) every other day. The treatment trial was terminated when one animal in any cohort had to be euthanized for tumour burden according to Institutional Animal Care and Use Committee regulations. The inhibitory effect of rapamycin on mTOR activity of treated tumours was verified by western analysis (Supplementary Fig. 2g ). The efficacy of rapamycin treatment was then calculated as the percentage of tumour growth inhibition of treated versus non-treated cohorts, after four doses (day 8 of trial) for WM239A cells, and six doses (day 12 of trial) for 1205LU cells. Indeed, GOLPH3-expressing tumours were significantly more sensitive to rapamycin in vivo (Fig. 5a-c and Supplementary Fig. 5 ). Therefore, we conclude that the biochemical effect of GOLPH3 on mTOR signalling is a critical aspect of its oncogenic function, because inhibition by rapamycin effectively blocked the growth advantage conferred by GOLPH3 in vivo. 
Discussion
In this study, integrative analyses of genome-wide copy number and expression data, coupled with reinforcing knockdown and overexpression assays in vitro and in vivo, led to the identification of GOLPH3 as a bona fide oncoprotein frequently targeted for copynumber gain/amplification in diverse human cancers. A suspect role for the Golgi apparatus in regulating cancer-relevant signalling has been speculated on the basis of the observation that some cytoplasmic membrane oncoproteins, such as RAS, can functionally signal when temporally present at the Golgi apparatus 24 . However, proteins such as GOLPH3 that are predominantly localized to the TGN have not been directly linked on a genetic level to cancer; therefore, GOLPH3 represents a first-in-class Golgi oncoprotein. Mechanistically, we show that the enhanced activation of mTOR signalling represents a molecular basis for the oncogenic activity of GOLPH3. In this light, enhanced and sustained mTOR activation in vivo would be expected to confer a significant growth advantage to cancer cells, a probable basis for increased GOLPH3 gene copy number or expression in a large fraction of human cancers.
Although we show through genetic and pharmacological studies that the activation of mTOR is essential for the tumorigenicity of GOLPH3, the precise structural and biochemical basis for its activity remains to be fully determined. Our molecular data on the physical interaction between GOLPH3 and the retromer complex, which is responsible for protein trafficking between endosomes and the TGN 16 , for the first time, to our knowledge, genetically implicates this biological process in cancer. This is consistent with recent reports on the essential role of the retromer and retrograde transport in regulation of the wntless receptor and proper secretion of the Wnt morphogen 25 , which is important in both normal and neoplastic development. Along the same line, depletion of Vps35 (also known as CG5625) in Drosophila inhibited endocytosis of RTKs with concomitant alterations in downstream signalling 26 . Taken together, these data raise the possibility that GOLPH3 might function with VPS35 and the retromer to regulate receptor recycling of key molecules, thereby influencing downstream signalling through mTOR.
It has recently been discovered that Vps74, the yeast homologue of GOLPH3, is required for proper docking and localization of glycosyltransferases to the Golgi apparatus 27, 28 . Protein glycosylation is one of the most prevalent forms of post-translational modification, and altered glycosylation is a hallmark feature of cancers 29 . It is noteworthy that glycosylation is known to be important for growth-factor activation of transmembrane receptors, because glycosylation mediates receptor sorting, ligand binding and endocytosis 29, 30 . Thus, it is plausible that human GOLPH3 might serve a similar function in glycosyltransferase docking as in S. cerevisiae, and therefore might influence the downstream mTOR signalling response through its effect on membrane RTKs.
The PI3K-AKT-mTOR signalling cascade is activated in nearly all cancers and hence represents an intense focus for cancer drug development. However, the clinical response to rapamycin and its analogues has been feeble 11 . Our demonstration of the role of GOLPH3 in activating mTOR signalling and conferring increased sensitivity to rapamycin in preclinical setting raises the possibility that GOLPH3 expression level or gene copy-number status may predict sensitivity to mTOR inhibitors. Indeed, end-point analysis of our preclinical treatment studies showed that rapamycin was significantly more effective against xenograft tumours expressing high levels of GOLPH3 (P 5 0.0268; 1205LU-GOLPH3 versus 1205LU-empty-vector tumour volumes at end-point; Supplementary Fig. 5b ), thereby suggesting that GOLPH3 levels may be a positive predictor of rapamycin sensitivity. Although the predictive value of GOLPH3 as a biomarker remains to be demonstrated, the formulation of this hypothesis highlights the importance of mechanistic insights beyond functional and clinicopathological validation in the translation of cancer genomics.
METHODS SUMMARY
Array-CGH profiles of melanoma, NSCLC and colon adenocarcinoma were analysed as previously described 31 . FISH analyses on TMAs of nine tumour types using 5p13 and CEP1 centromeric probes determined frequency of copy number gain. Real-time quantitative genomic PCR in informative samples containing the 5p13 CNA defined a MCR containing four genes, and integration with NSCLC tumour and cell line transcriptome profiles identified MCR-resident genes with copy-number-correlated expression patterns. Oncogenic activity was assayed in vitro (proliferation, MEF transformation, and anchorage-independent growth in soft agar) and in vivo (subcutaneous tumour growth) through loss-of-function (by RNAi targeting GOLPH3) and gain-of-function (by overexpression of GOLPH3) in primary (MEF, HMEL) and transformed mouse and human cells. The yeast two-hybrid screen was performed using a human cDNA brain library with a GOLPH3 bait construct. Serum-and EGF-induced mTOR and AKT activity was measured with pS6K(Thr 389) and pAKT(Ser 473) as readout by western blotting. Total mTOR and pS6K(Thr 389) were used to quantify relative protein expression level on tumour tissue microarrays by AQUA to correlate expression with copy-number status determined by FISH. Rapamycin sensitivity was determined by drug treatment in in vivo xenograft assays.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature. Table summarizing data from the rapamycin-treatment xenograft studies in a and b at the same time point (day 8, after four doses). Rap, rapamycin; Veh, vehicle. Note 1205LU-GOLPH3 tumours treated with vehicle grew 2.53 in size during the 8 days of treatment. In comparison, WM239A-GOLPH3 tumours grew 5.83 in size during the same period of 8 days. The %TGI in these two cohorts of tumours was similar, at 81.9% and 80.9%, respectively, indicating that the growth rate did not impact on the response to rapamycin.
METHODS
Cell lines. All cell lines were propagated at 37 uC and 5% CO 2 in humidified atmosphere in RPMI 1640 medium (Invitrogen) supplemented with 10% heatinactivated FBS. CRL-5889, SK-MEL-5, 1205LU, A549 and 293T cells were obtained from the American Type Culture Collection. Sbcl2, WM239A and hTERT/CDK4(R24C)/p53DD/BRAF(V600E) melanocytes (HMEL) have been described before 12, 32 . Plasmids, retroviral transduction, and siRNA transfection. The retroviral HA-GOLPH3 expression clone, pBABE-HA-GOLPH3, was constructed by subcloning PCR-generated GOLPH3 cDNA (NCBI accession NM_022130) into pBABE-puro-HA (Addgene). The GOLPH3 siRNA-resistant construct pBABE-HA-GOLPH3 (siRES), which encodes wild-type GOLPH3 protein with nucleotide sequence mutated to resist siRNA against GOLPH3 (siRNA 3), was constructed by site-directed mutagenesis of the pBABE-HA-GOLPH3 vector using primers 59-TGTATGTTAATTGAATTAGCATTGAGGGGTAGATTGC AACTAGAGGCTTGTGGAATGAGACG-39, and 59-CGTCTCATTCCACAA GCCTCTAGTTGCAATCTACCCCTCAATGCTAATTCAATTAACATACA-39. pEF-Dest51-GOLPH3, pLenti4/TO/V5-DEST-GOLPH3 and pLenti6/V5/ DEST-VPS35 were constructed via gateway recombination cloning (Invitrogen) into pEF-Dest51, pLenti4/TO/V5-DEST and pLenti6/V5/DEST (Invitrogen), respectively, using pDONR223-GOLPH3 and pDONR223-VPS35 entry clones (Center for Cancer Systems Biology at the Dana-Farber Cancer Institute) according to the manufacturer's protocol. The yeast bait construct, pGBKT7-GOLPH3, was constructed by inserting the GOLPH3 fragment from pBABE-HA-GOLPH3 into the pGBKT7 bait vector (Clontech). The tetinducible GOLPH3 cell line, HMEL-tet-GOLPH3, was created using the T-Rex lentiviral expression system (Invitrogen) and pLenti4/TO/V5-DEST-GOLPH3 according to the manufacturer's protocol. Lentivirus and retrovirus were prepared by co-transfecting 293T cells with the above-mentioned vector backbones and standard virus packaging systems for subsequent collection of viral supernatants. All overexpression studies were performed with newly transduced stable cells lines. In HMEL-tet-GOLPH3 cells, GOLPH3 expression was stimulated by the addition of 2 mg ml 21 doxycycline for 48 h for all assays. . Cells were incubated 48-72 h before collection for all assays. Unless otherwise indicated, GOLPH3 knockdown experiments were conducted using siRNA 3. For soft agar colony formation and proliferation assays, cells were plated 24 h after siRNA transfection. Cross-tumour array-CGH and expression analysis. Cross-tumour array-CGH analysis of malignant melanoma, NSCLC and colon adenocarcinoma was performed as described 31 using melanoma and colon adenocarcinoma data previously submitted to the Gene Expression Omnibus (accession numbers GSE7606 and GSE7604, respectively). The NSCLC data set has been previously described 33 and can be found at http://genomic.dfci.harvard.edu/. The numbers of 5p13 amplifications identified in array-CGH profiles were: melanoma, 6 (2 focal) present among 88 tumour profiles; NSCLC, 18 (1 focal) present among 67 profiles (15 cell lines and 52 tumours); colorectal cancer, 4 present among 81 profiles (38 cell lines and 43 tumours). For expression analysis of MCR-resident genes, NSCLC expression data accompanying array-CGH profiles was analysed. Among the 42 samples with both array-CGH 22K profiles and Affymetrix HGU133plus2 profiles available, 14 contained the 5p13 amplification event. Expression values for each gene (values from several probes for the same gene were averaged) from two groups (with or without amplification) were compared by two-sample t-test, and the significance level was adjusted with Bonferroni correction. TMA-FISH. The following tissue microarrays were purchased from Cybrdi: CC04-01-004 lung carcinoma, CC11-11-005 ovarian carcinoma, CC08-01-002 breast carcinoma, CC05-21-001 colon adenocarcinoma, CC03-01-003 liver carcinoma and CC19-11-007 prostate carcinoma. The multiple myeloma tissue microarray was from TriStar. PA802 pancreatic carcinoma and ME1001 melanoma tissue microarrays were from US Biomax. FISH was prepared following standard protocols. BAC RP11-437P15 was used to mark the region of gain at 32 Mb on chromosome 5 (5p13). The centromere-specific CEP1 probe (Abbott Laboratories) served as a ploidy reference. FISH signal evaluation and acquisition were performed manually using filter sets and software developed by Applied Spectral Imaging. A signal to reference ratio greater than 1.5 was considered as gain; a ratio above $2.5 was considered as a high amplification level.
TMA-IHC and AQUA. Arrays were deparaffinized with xylene, rehydrated and antigen-retrieved by pressure cooking for 20 min in citrate buffer (pH 6). Slides were pre-incubated with 0.3% BSA in 0.1 M Tris-buffered saline (TBS, pH 8) for 30 min at room temperature. Lung cancer TMAs were then incubated overnight with a cocktail of either the mTOR primary antibody (1:200; rabbit monoclonal, clone 7C10, Cell Signaling Technology) and a mouse monoclonal anti-human cytokeratin antibody (1:100 in BSA/TBS; clone AE1/AE3, M3515, Dako) or the pS6K(Thr 389) primary antibody (1:200; mouse monoclonal, clone 1A5, Cell Signaling Technology) and a wide-spectrum rabbit anti-cow cytokeratin antibody (1:100 in BSA/TBS; Z0622, Dako). For the melanoma cohort, a mouse monoclonal S100 antibody (15E2E2, BoGenex) and a rabbit polyclonal S100 antibody (Z0311, Dako) (both 1:100 in BSA/TBS-Tween) were used instead of the mouse and rabbit cytokeratin, respectively. This was followed by a 1-h incubation with Alexa 546-conjugated goat anti-mouse secondary antibody (A11003, Molecular Probes) diluted 1:100 in rabbit EnVision reagent (Dako), and Alexa 546-conjugated goat anti-rabbit secondary antibody (A11010, Molecular Probes) diluted 1:100 in mouse EnVision reagent (Dako), for mTOR and pS6K, respectively. Cyanine 5 (Cy5) directly conjugated to tyramide (Perkin-Elmer) at a 1:50 dilution was used as the fluorescent chromagen for target detection. Prolong mounting medium (ProLong Gold, Molecular Probes) containing DAPI was used to identify tissue nuclei. Serial sections of a smaller TMA consisting of 30 lung cancer specimens (NSCLC 'test' array) were stained aside both cohorts to confirm assay reproducibility. H1299 and A431 cells were used as positive controls as indicated by the manufacturer. Negative control sections, in which the primary antibody was omitted, were used for each immunostaining run.
AQUA allows exact measurement of protein concentration within subcellular compartments, as described in detail elsewhere 18 . In brief, a series of highresolution monochromatic images were captured by the PM-2000 microscope. For each histospot, in-and out-of-focus images were obtained using the signal from the DAPI, cytokeratin and S100-Alexa 546 (for lung cancer and melanoma, respectively) and mTOR/pS6K-Cy5 channels. mTOR and pS6K were measured using a channel with emission maxima above 620 nm, to minimize tissue autofluorescence. Tumour was distinguished from stromal and non-stromal elements by creating a tumour 'mask' from the cytokeratin and S100 signal for lung cancer and melanoma specimens, respectively. This created a binary mask (each pixel being either 'on' or 'off') on the basis of an intensity threshold set by visual inspection of histospots. The AQUA score of the protein of interest in each subcellular compartment was calculated by dividing the signal intensity (scored on a scale from 0 to 255) by the area of the specific compartment. Specimens with less that 5% tumour area per spot were not included in automated quantitative analysis for not being representative of the corresponding tumour specimen.
For statistical analysis, Pearson's correlation coefficient (r) was used to assess the correlation between log-normalized mTOR and pS6K AQUA scores, as well as the same scores on serial cuts of the NSCLC test array. Evaluation of the interarray reproducibility did not show significant differences between serial sections of the NSCLC test array (Pearson's r 5 0.95, P , 0.0001). Ratios of cytoplasmic-to-nuclear expression for mTOR and pS6K were used to normalize for individual variation between groups, and were compared to GOLPH3 gene copy number. The association between mTOR, pS6K AQUA scores and GOLPH3 gene copy number (as determined by 5p13 FISH) with clinicopathologic parameters (age, gender, histological type and tumour differentiation) were analysed using Spearman's rank test. GOLPH3 copy-number status was also binarized on the basis of FISH signals as normal (,1.5) and gain ($1.5), and correlated as non-continuous variable with all other parameters using Pearson's correlation. Quantitative PCR and copy number. Genomic DNA was prepared from cell lines and melanomas with the Wizard kit (Promega), and total RNA was isolated using Trizol reagent (Invitrogen) and RNeasy columns (Qiagen). DNA copy numbers and relative expression levels were determined by real-time PCR using SYBR green I (Qiagen) detection chemistry, and the Stratagene MX3000p detection system according to the manufacturer's protocol. The comparative cycle threshold method was used to quantify target gene or mRNA copy numbers in the samples. For quantification of gene copy numbers, we compared copy numbers in tumour DNA to copies in normal human control DNA (Promega). The DNA copy number normalization reference was Line-1 DNA copy number. Anchorage-independent growth. Soft-agar assays were performed on 6-well plates in triplicate. For each well, 1 3 10 4 cells were mixed thoroughly in cell growth medium containing 0.4% SeaKem LE agarose (Fisher) in RPMI plus 10% FBS, followed by plating onto bottom agarose prepared with 0.65% agarose in RPMI and 10% FBS. Each well was allowed to solidify and subsequently covered in 1 ml RPMI and 10% FBS, which was refreshed every 4 days. Colonies were stained with 0.05% (w/v) iodonitrotetrazolium chloride (Sigma) and scanned at
